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Abstract
The latest list of reimbursed medicines includes, as a new addition, metformin for the treatment of polycystic ovary syndrome (PCOS), 
which is extremely important for practicing physicians. While this paper briefly summarises the current state of knowledge on PCOS, 
its main aim is to remind the reader about the effectiveness of metformin in women with PCOS in controlling glycaemia, increasing 
tissue sensitivity to insulin and affecting endothelial function, vascular inflammation, lipid profile and other risk factors of atherosclero-
sis, which suggests its cardioprotective effects. The paper also discusses the clinical effect of metformin relative to hyperandrogenism, 
menstrual cycle disorders and ovulation induction. The paper concludes with an algorithm for the diagnosis and management of PCOS. 
(Endokrynol Pol 2013; 64 (5): 409–414)
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Streszczenie
Ostatnia lista leków refundowanych uwzględnia po raz pierwszy metforminę w terapii choroby wielotorbielowatych jajników ( PCOS), 
co jest niezwykle istotne dla lekarzy praktyków. W artykule skrótowo podsumowano stan wiedzy na temat PCOS. Jednak głównym jego 
przesłaniem było przypomnienie efektywności terapii metforminą u kobiet z PCOS w kontroli glikemii, zwiększeniu wrażliwości tkanek na 
insulinę, wpływie na czynność śródbłonka, proces zapalny w naczyniach, profil lipidowy oraz inne czynniki ryzyka miażdżycy, co świadczy 
o jej działaniu kardioprotekcyjnym. Ponadto omówiono efekt kliniczny odnośnie hiperandrogenizmu, zaburzeń cyklu miesiączkowego 
oraz indukcji owulacji. Podsumowaniem artykułu jest zaprezentowanie schematu postępowania diagnostyczno-terapeutycznego PCOS. 
(Endokrynol Pol 2013; 64 (5): 409–414)
Słowa kluczowe: PCOS, zaburzenia metaboliczne, metformina
The latest list of reimbursed medicines has been 
a pleasant surprise: it now includes metformin when 
prescribed off-label to patients with prediabetes but 
also, importantly, when prescribed off-label to patients 
with PCOS. We finally have legal grounds for prescrib-
ing reimbursed metformin to women with PCOS, 
which was previously not possible, so we now have 
the green light. 
I will now try to remind you why this is all so im-
portant and provide you with some new facts about the 
old, safe and inexpensive treatment with this medicine.
PCOS is one of the most common endocrinopa-
thies in women of reproductive age. Its prevalence 
is estimated at about 6–10%, or even 15% when the 
diagnosis is based on the Rotterdam criteria [1]. Three 
sets of diagnostic criteria for PCOS currently exist. The 
first, proposed by the National Institutes of Health 
(NIH), combines menstruation disorders and chronic 
anovulation with hyperandrogenism [2]. According to 
the Rotterdam criteria, the diagnosis of PCOS may be 
made if any two out of the following three abnormali-
ties are present: 1) chronic anovulation; 2) clinical and/ 
/or biochemical hyperandrogenism; and 3) polycystic 
ovaries on pelvic ultrasound [3]. According to the cri-
teria most recently proposed by the Androgen Excess 
and PCOS Society, the diagnosis of PCOS requires both 
the presence of clinical and/or biochemical signs of 
hyperandrogenism and the presence of menstruation 
disorders with chronic anovulation or a characteristic 
sonographic morphology of the ovaries [4]. Each set of 
the diagnostic criteria of PCOS additionally requires 
exclusion of other causes of hyperandrogenism, such as: 
congenital adrenal hyperplasia, Cushing’s syndrome, 
androgen-secreting tumours, hyperprolactinaemia, 
acromegaly, and thyroid diseases (Fig. 1).
Considerable controversy surrounds the definition 
of PCOS and the diagnosis of PCOS and of its main 
components. There is no single diagnostic criterion for 
this syndrome. There is no straightforward relationship 
between the severity of clinical and biochemical signs 
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of hyperandrogenism. The clinical signs of hyperandro-
genism, particularly hirsutism, are believed to be more 
useful in the diagnosis of PCOS than hyperandroge-
naemia. On the other hand, hirsutism may be absent in 
women with elevated androgen levels, such as in Asian 
women, which is most likely due to ethnic factors. In 
addition, polycystic ovaries are found only in 50% of 
hirsute women [5]. Measurement of free testosterone 
levels is recommended to demonstrate hyperandroge-
naemia. Assessment of total testosterone levels may not 
be sufficient, as they are within the reference range in 
about 14% of women with PCOS [5]. If free testosterone 
cannot be determined, the free androgen index (FAI) 
may be used. The FAI is a ratio of total testosterone level 
in nmol/l to sex hormone binding globulin (SHBG) level 
in nmol/l multiplied by 100%.
The very definition of chronic anovulation is contro-
versial. It is believed that fewer than 6–8 menstruations 
per year is an indicator of chronic anovulation. 43% 
of women with PCOS suffer from oligomenorrhoea 
(where the duration of menstrual cycles ranges from 35 
to 199 days), 21% from secondary amenorrhoea (where 
the duration of menstrual cycles exceeds 199 days), and 
7% from primary amenorrhoea [1–6]. It should, how-
ever, be noted that up to 32% of women ovulate spon-
taneously despite PCOS [6]. Sonographic diagnosis of 
polycystic ovaries requires the demonstration, in one or 
both ovaries, of 12 or more peripherally located follicles 
measuring 2 to 9 mm in diameter or an ovarian volume 
of more than 10 cm2. If a follicle measuring more than 
10 mm in diameter is identified, the ultrasound scan 
needs to be repeated. It should be noted that about 30% 
of women with normal menstruation and with normal 
androgen levels may have polycystic ovaries, in which 
case the diagnosis of PCOS is not warranted.
The pathogenesis of PCOS has not been com-
pletely elucidated and is multifactorial, with genetic 
and environmental factors being implicated. Those 
genes thought to be involved in the pathogenesis 
of PCOS include genes associated with steroidogen-
esis, regulation of gonadotropin secretion, effects of 
insulin, obesity, factors regulating the body’s energy 
expenditure, and genes associated with chronic in-
flammation [7]. A primary defect in the synthesis and 
metabolism of androgens in the ovaries resulting in an 
increased secretion of these hormones by the gonads 
is believed to be responsible for the development of 
PCOS. Neuroendocrine abnormalities leading to an 
increased secretion of luteinising hormone (LH) are 
also observed.
Figure 1. An algorithm for the diagnosis and management of PCOS
Rycina 1. Schemat postępowania diagnostyczno-terapeutycznego w PCOS
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Numerous studies have demonstrated a patho-
genetic association of PCOS with insulin resistance 
and hyperinsulinaemia. Insulin resistance is thought 
to be caused by defects in the insulin receptor and 
post-receptor components of the insulin signalling 
pathway. According to Dunaif et al., in about 50% of 
patients with PCOS, insulin receptor autophospho-
rylation is impaired [8]. Phosphorylation of serine 
residues of this receptor interferes with its function 
and with downstream signalling. Phosphorylation 
of insulin receptor substrate 1 (IRS-1), stimulated by 
tumour necrosis factor alpha (TNF-a) and leading to 
decreased activity of tyrosine kinase, may also play 
a role here [9]. Phosphorylation of serine residues may 
occur in cytochrome P450c17 and lead to increased 
activity of 17,20-lyase and 17a-hydroxylase. Free fatty 
acids and proinflammatory cytokines are believed to 
cause excessive phosphorylation of serine residues in 
the insulin receptor and cytochrome P450c17 resulting 
in insulin resistance and hyperandrogenism in PCOS 
[10]. Vitamin D deficiency and polymorphisms of vita-
min D receptor genes (Cdx2, BsmI, FokI, ApaI and TaqI) 
have recently been implicated in the aetiology of the 
metabolic abnormalities in PCOS [11].
Insulin resistance in PCOS is mainly evident in the 
metabolic effects of insulin. Hyperinsulinaemia second-
ary to insulin resistance leads to an increased ovarian 
response to gonadotropins that is mainly manifested 
by overexpression of LH and IGF-1 receptors [12, 13]. 
Insulin increases the sensitivity of immature granu-
losa cells to LH, proliferation of thecal cells and the 
activity of enzymes required for androgen synthesis: 
3β-hydroxysteroid dehydrogenase, 17a-hydroxylase, 
and 17,20-lyase [14–18]. Another mechanism whereby 
insulin resistance causes hyperandrogenaemia involves 
reduced synthesis of SHBG, which results in increases 
in the bioavailability of testosterone to peripheral tis-
sues [19]. Hyperinsulinaemia may also increase the 
activity of the hypothalamic-pituitary-adrenal axis and, 
as a result, the secretion of androgens by the adrenal 
glands [20].
According to various studies, up to 70% of women 
with PCOS are resistant to insulin, with about 50% of 
them being obese [10, 21]. Insulin resistance and obesity 
are also associated with a number of other metabolic 
abnormalities observed in PCOS. The prevalence of 
metabolic syndrome is 2–4 times higher compared 
to healthy controls [22, 23]. Abnormalities of carbo-
hydrate metabolism observed in women with PCOS 
include an increased frequency of impaired glucose 
tolerance and of type 2 diabetes mellitus compared to 
controls matched for age and body mass index (BMI) 
[24]. Women with PCOS are also at a ten-fold higher 
risk of gestational diabetes than women in the general 
population [25]. Studies investigating metabolic abnor-
malities in PCOS have shown that the affected women 
have abnormalities of lipid metabolism manifested 
by decreased HDL-cholesterol levels and increased 
LDL-cholesterol and triglyceride levels [10]. Vascular 
wall abnormalities, such as an increased intima-media 
thickness [26] or the presence of calcium deposits in 
arterial walls, both indicative of an increased cardio-
vascular risk, have also been reported in patients with 
PCOS. The presence of endothelial dysfunction, an 
early marker of ischaemic heart disease in patients with 
PCOS, has been demonstrated in studies investigating 
abnormalities of vascular dilation relative to blood flow 
(flow-mediated dilation, FMD) [28, 29]. FMD has been 
shown to correlate positively with the insulin resistance 
index HOMA and negatively with the insulin sensitivity 
index QUICKI. There have also been reports of elevated 
levels of chronic inflammation markers, prothrombotic 
factors and factors associated with oxidative stress, such 
as: C-reactive protein, homocysteine, paraoxonase-1, 
fibrinogen, plasminogen activator inhibitor-1 (PAI-1), 
interleukin-6, TNF-a, and nucleic factor kappa-B (NF-
kB) [30–37].
In conclusion, patients with PCOS have multiple 
cardiometabolic risk factors: obesity, insulin resist-
ance, atherogenic lipid abnormalities, elevated levels 
of chronic inflammation markers and elevated levels 
of fibrinolysis markers. In order to prevent premature 
atherosclerosis, cardiovascular disease and type 2 dia-
betes mellitus in PCOS it is therefore necessary to treat 
these risk factors. Non-pharmacological interventions, 
namely lifestyle modifications and increased physical 
activity, should be at the forefront. However, these 
interventions may not always be effective if employed 
alone. A recent metaanalysis has shown that that while 
lifestyle modifications can reduce body mass, total 
testosterone levels, fasting insulin levels, hirsutism as 
assessed using the Ferriman-Gallwey score, and the 
waist-to-hip ratio (WHR), they do not affect BMI, SHBG 
levels, FAI, fasting glucose levels or lipid profile [24]. 
An important role in the management of many as-
pects of PCOS, particularly in the management of the 
metabolic abnormalities in the course of the disease, is 
therefore played by pharmacological treatment, par-
ticularly by treatment with drugs that increase insulin 
sensitivity, with metformin being the most important 
one.
Metformin belongs to the biguanide class of drugs. 
Although it has been available for more than 50 years, 
it continues to be widely used in clinical practice and 
its indications are expanding. The principal effect of 
metformin is to decrease insulin resistance. In addition, 
metformin exerts a pleiotropic protective effect on the 
cardiovascular system, which effect cannot be solely 
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explained by improved glucose levels. Metformin de-
creases hepatic synthesis of glucose (gluconeogenesis), 
decreases absorption of glucose from the intestines and 
increases peripheral uptake and metabolism of glucose. 
An important effect of metformin at the cellular level 
is to increase the activity of the enzyme AMP kinase, 
which plays a crucial role in the regulation of carbohy-
drate and lipid metabolism [38]. AMP kinase affects, 
among other processes, the function of the glucose 
transporter GLUT4 and free fatty acid oxidation, which 
may result in decreased lipolysis in adipocytes [39].
Despite previously published reports of body mass 
reduction in patients treated with metformin, recent 
metaanalyses have not confirmed weight-reducing ef-
ficacy of metformin [40, 41]. Metformin seems to have 
a neutral effect on body mass, although it may cause 
redistribution of fat from the active visceral adipose tis-
sue to the metabolically inactive subcutaneous fat [42]. 
Metformin treatment beneficially affects lipid profile by 
decreasing total cholesterol, LDL-cholesterol and tri-
glyceride both in patients with type 2 diabetes mellitus 
and in non-diabetic patients [41, 43]. Numerous stud-
ies have shown beneficial antiatherosclerotic effects of 
metformin, such as improved endothelium-dependent 
vasodilation [44], decreased levels of endothelial activa-
tion markers, sVCAM-1 and E-selectin, decreased levels 
of PAI-1 [45], decreased levels of CRP [46], suppressed 
monocyte adhesion to cultured vascular wall cells and 
suppressed monocyte conversion to foam cells [47]. 
Metformin may also exert an antioxidant effect by 
decreasing the formation of advanced glycation end-
products (AGE) [48].
There is also evidence of beneficial effects of met-
formin in non-alcoholic fatty liver. An improvement 
in liver function tests (decrease in liver aminotrans-
ferase levels), a decrease in liver fat and an increase in 
insulin sensitivity have been shown in patients with 
non-alcoholic fatty liver treated with metformin [49]. 
Another potential action of insulin is its antitumour ef-
fect. Observational studies have shown a reduction of 
cancer-related mortality in patients with type 2 diabetes 
mellitus treated with metformin [50].
Metformin is used in the treatment of many com-
ponents of PCOS, with type 2 diabetes mellitus, im-
paired glucose tolerance and insulin resistance being 
the principal indications. Numerous publications have 
also reported positive effects of metformin on other 
cardiometabolic risk factors present in PCOS. These 
effects include improved endothelial function [51, 52], 
improved levels of inflammation markers [52, 53] and 
improved coronary reserve [54]. A metaanalysis has 
shown a decrease in LDL-cholesterol levels in patients 
with PCOS treated with metformin [41] and an obser-
vational study has revealed a dose-dependent (1,500 
mg vs 2,550 mg) body mass reduction in women with 
this condition [55].
Although a reduction in androgen levels by met-
formin has been reported in several studies [56, 57], this 
biguanide is not very effective in reducing the severity 
of hirsutism in PCOS. Most studies have shown no evi-
dence of hirsutism-reducing activity of metformin [58, 
59], which is why this drug is not used in the manage-
ment of hyperandrogenism. The principal role in the 
treatment of menstruation disorders is played by oral 
contraceptives. The possible contraindications to oral 
contraceptives in women with PCOS should, however, 
be borne in mind. These agents may further exacerbate 
insulin resistance and increase cardiovascular and 
thrombotic risk, which is why it is beneficial to combine 
them with metformin. However, according to recent 
studies, oral contraceptives do not increase metabolic 
risk in women with PCOS [57].
The reported percentage of women in whom met-
formin regulates their menstrual cycle varies between 
23% and 90%, while the results of studies investigating 
the impact of this drug on ovulation and pregnancy 
rates remain inconclusive. According to some studies, 
metformin increases ovulation and pregnancy rates 
from 5% to 18%, while according to other studies, 
similar effects may be obtained by lifestyle modifica-
tions and weight reduction [60]. A Cochrane review 
has shown that metformin treatment may result in 
a four-fold increase in the ovulation rate and a three-
fold increase in the pregnancy rate versus placebo or 
no treatment, although these results did not reach sta-
tistical significance [58]. According to the most recent 
consensus statements, the addition of metformin to 
clomifene in the treatment of infertility in women with 
PCOS results in no evident benefit [61]. An important 
issue in PCOS is the increased risk of miscarriage of 
up to 30–50% in women with this condition. During 
pregnancy, the levels of glycodelin and IGFBP-1 fall, 
and these abnormalities are worsened by hyperinsu-
linaemia. By stimulating glycodelin secretion, met-
formin may reduce the incidence of early miscarriage 
in women with PCOS [62, 63].
Metformin treatment in patients with PCOS not 
only improves glycaemic control and tissue sensitivity 
to insulin but also — as a result of its effects on endothe-
lial function, vascular inflammation, lipid profile and 
other risk factors of atherosclerosis — exerts cardiopro-
tective effects and may reduce cardiovascular risk. Pa-
tients with PCOS are a heterogenous group in terms of 
phenotypes distinguished on the basis of specific clini-
cal presentations necessary for the diagnosis. This clas-
sification distinguishes the ‘classic’ phenotype in which 
all the three criteria required for diagnosis are present 
(oligomenorrhoea, hyperandrogenism and polycystic 
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ovaries [phenotype A]) and three other phenotypes 
which are combinations of two of the criteria required 
for diagnosis (oligomenorrhoea and hyperandrogen-
ism [phenotype B]; hyperandrogenism and polycystic 
ovaries [phenotype C]; oligomenorrhoea and polycystic 
ovaries [phenotype D]. Taking this classification into 
consideration, the most common metabolic abnormali-
ties were observed in the ‘classic’ phenotype [21]. 
Figure 1 illustrates an algorithm for the diagnosis 
and management of PCOS which takes into account the 
recommendations of the ESHRE/ASRM (Amsterdam, 
2012). In the diagram, the starting point for therapeutic 
interventions is the presence of cardiovascular risk factors, 
i.e. obesity, abnormalities of carbohydrate metabolism, 
abnormalities of lipid metabolism, and hypertension. 
Please do not forget to measure vitamin D levels in 
patients with PCOS. I hope you find the diagram useful 
in your everyday practice.
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